LY3884961 + Sirolimus + Methylprednisolone for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Oct 2019: Trial registered, NCT04127578
  2. 3 Jan 2020: Trial started, NCT04127578

The trials

NCT04127578: Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

State
Under way
Phase
Phase 1 and Phase 2
People
32 planned
Started
3 Jan 2020
Primary completion
31 Aug 2031
Arms
Dose Level 1, Dose Level 2
Results
None posted
  1. 15 Oct 2019: Trial registered
  2. 3 Jan 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.